Results 271 to 280 of about 528,594 (306)
Some of the next articles are maybe not open access.

Sorafenib in melanoma

Expert Opinion on Investigational Drugs, 2012
INTRODUCTION: Sorafenib is an orally available multi-kinase inhibitor that inhibits tumor proliferation by targeting multiple kinases including the vascular endothelial growth factor receptors VEGFR1, VEGFR2, VEGFR3 and the platelet-derived growth factor receptor PDGFR, and it targets tumor progression by inhibiting FLT3, C-Kit and BRAF.
Mangana, J   +3 more
openaire   +4 more sources

Nevoid Melanoma

Surgical Pathology Clinics, 2009
This article discusses the key features of nevoid melanoma. Gross features, microscopic features, immunohistochemistry, differential diagnosis, diagnosis, prognosis, and treatment are also discussed.
A Hafeez, Diwan, Alexander J, Lazar
openaire   +3 more sources

“Lentiginous Melanoma”

Advances in Anatomic Pathology, 2014
On the basis of a critical review of published literature, it is concluded that there is as yet insufficient evidence to conclude that the melanocytic lesion, which is currently known as "lentiginous melanoma," is a full-fledged melanoma, with the capacity to metastasize to distant sites and to cause the demise of the patient.
openaire   +3 more sources

Desmoplastic Melanoma

Clinics in Laboratory Medicine, 2009
Desmoplastic melanoma (DM) is a variant of spindle cell melanoma characterized by the presence of abundant fibrous matrix. It is typically found in the head and neck region on chronically sun-damaged skin of older individuals. Early detection is uncommon, because its clinical features are not distinctive. DM is prone to misdiagnosis not only clinically
openaire   +4 more sources

Familial Melanoma

Clinical and Experimental Dermatology, 1992
The presence of large numbers of moles, atypical in appearance and distribution typifies the atypical mole syndrome. The syndrome may occur in one individual alone or in an autosomal-dominant fashion in his/her family. The presence of this phenotype indicates an increased risk of melanoma, although the risk varies according to the presence or absence ...
openaire   +2 more sources

Melanoma

New England Journal of Medicine, 2006
Arlo J, Miller, Martin C, Mihm
openaire   +2 more sources

Melanoma genomics

Current Oncology Reports, 2004
Sophisticated molecular techniques that have recently become available permit analysis of genome-wide changes in gene copy number (DNA) or expression (RNA). These genomic strategies have the potential to transform our view of cancer biology and pathogenesis.
openaire   +2 more sources

Melanoma

Current Problems in Surgery, 1971
C O, Knutson, J M, Hori, J S, Spratt
openaire   +2 more sources

Melanoma

The Lancet, 1996
JasonK. Rivers, J.K. Rivers
openaire   +4 more sources

Melanoma.

Nihon rinsho. Japanese journal of clinical medicine, 2016
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
openaire   +2 more sources

Home - About - Disclaimer - Privacy